Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-003495
Filing Date
2025-01-14
Accepted
2025-01-14 17:30:56
Documents
2
Period of Report
2025-01-10

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm253166-2_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm253166-2_4seq1.xml 4 6050
2 EXHIBIT 24 tm253166d2_ex24.htm EX-24 7715
  Complete submission text file 0001104659-25-003495.txt   15537
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Issuer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ARYX THERAPEUTICS,INC. 6300 DUMBARTON CIRCLE FREMONT CA 94555
Business Address
Varian John (Reporting) CIK: 0001416176 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33958 | Film No.: 25530333